Journey Medical vs Rockwell Medical
DERM and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DERM and RMTI compare
Journey Medical is the larger company, worth 4.3 times as much as Rockwell Medical ($122M against $28.3M).
Journey Medical grew revenue faster over the last twelve months (17.0% versus −4.0% for Rockwell Medical).
Journey Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −7.8% at Rockwell Medical.
Rockwell Medical scores higher on the StockData Score (11 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DERM | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $122M | $28.3M |
| Share price | $4.33 | $7.03 |
| Change, 1 year | −52.3% | −26.4% |
| Change, 5 years | −50.7% | −86.7% |
| Beta (5Y) | 0.68 | 1.80 |
| Employees | 58 | 157 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× | 0.4× (better) |
| P/B | 3.8× | 0.9× (better) |
| P/FCF | – | 34.2× |
| FCF yield | – | 2.9% |
| Fair value | $5.70 | $32.08 |
| Margin of safety | 24.1% | 78.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.0% (better) | −4.0% |
| Revenue growth, 5Y average | 6.8% (better) | 2.2% |
| Profitability | ||
| Gross margin | 65.9% (better) | 18.1% |
| Operating margin | −2.9% (better) | −7.1% |
| Net margin | −7.3% (better) | −7.8% |
| FCF margin | – | 1.1% |
| Return on equity | −17.6% | −16.1% (better) |
| Return on invested capital | −5.2% (better) | −19.5% |
| Financial health | ||
| Debt / equity | 0.79 | 0.27 (better) |
| Interest coverage | −0.6× (better) | −4.6× |
| Current ratio | 1.48 | 2.47 (better) |
| Altman Z-score | 0.55 (better) | −7.86 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.8% | 0.05% |
| Held by insiders | 15.3% | 100% |
| Insider net buying, 12 months | – | −$11.6K |
| Short interest, % of float | 12.9% | – |
Go deeper
- DERM stock overview
- DERM income statement
- DERM valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.